The microbial-mammalian symbiosis plays a critical role in metabolic health. Microbial metabolites emerge as key messengers in the complex communication between the gut microbiota and their host. These chemical signals are mainly derived from nutritional precursors, which in turn are also able to modify gut microbiota population. Recent advances in the characterization of the gut microbiome and the mechanisms involved in this symbiosis allow the development of nutritional interventions. This review covers the latest findings on the microbial-mammalian metabolic axis as a critical symbiotic relationship particularly relevant to clinical nutrition.
INTRODUCTION
Humans have evolved as part of a critical symbiotic relationship with their gut microbes. The gut ecosystem harbours thousands of microbial species and millions of genes, integrating a number of co-evolved microbial metabolic reactions encoded in the gut metagenome complementing endogenous metabolic processes encoded in the mammalian genome. High-throughput technologies such as metagenomics and metabolomics provide novel insights into this complex ecosystem, which is now recognized to have a key impact in the development and progression of diseases such as cardiometabolic disorders, irritable bowel syndrome and cancer.
The human gut provides commensal microbiota with a specific biotope with an almost constant supply of diet-derived and host-derived substrates for bacterial fermentation, thus providing key nutrients and energetic needs for the bacterial community and its human host [1] . Beneficial cross-feeding in this symbiotic relationship is best exemplified by the bacterial breakdown of otherwise indigestible polysaccharides and fibres into monosaccharides and short-chain fatty acids (SCFAs) [1] , and the rapid fucosylation of the host intestinal epithelium to sustain bacterial populations during sickness [2] . However, the range of metabolites produced by gut microbiota goes beyond simple metabolism and also includes microbial metabolites that act as chemical messengers, binding human target proteins and thereby impacting signalling pathways and metabolic and inflammation-related processes in the host [3 & ,4 ]. In this review, we briefly present the ecological structure of the microbiome and address selected examples of how nutrients are converted by the gut microbiota into chemical signals with a strong impact on host physiology and behaviour. We also revisit recent progress in novel tools to remodel the gut bacterial community (e.g. dietary interventions, use of antibiotics, prebiotics and probiotics, faecal transplantation) and its relevance as personalized approaches targeting key features of the microbialmammalian metabolic axis.
THE GUT MICROBIOME ARCHITECTURE
The gut microbiome is a highly complex ecosystem. Every person presents a unique combination of microbial species making everyone's microbiome unique. Several thousand species have been reported and result in combinations of more than 10 million individual bacterial genes, which have been catalogued [5 && ]. The gut ecology can be divided into core species that are present in pretty much everyone of us and rare species which are only observed in a small proportion of the population. Moreover, enteric bacterial populations tend to converge towards three distinct community types, called enterotypes [6, 7] . This particular architecture of the gut microbiome is not binary, but corresponds to a continuous distribution along a spectrum. These enterotypes are not related to gender, age and geography, and are dominated by one phylum: Bacteroides, Prevotella or Ruminococcaceae.
Variations related to the microbiome architecture are manifold. Microbial gene richness is variable in human populations and has been tied to metabolic health: people with a high microbial gene count are healthier than people with a low microbial gene count who tend to have metabolic syndrome [8 && ]. This is also the case for irritable bowel syndrome (IBS) in which patients with IBS have a lower ecological diversity than healthy controls [9, 10] . Obesity is associated with an imbalance between two major phyla, Bacteroidetes and Firmicutes, which is observed in both animal model and human populations [11] .
FACTORS AFFECTING THE GUT MICROBIAL ECOLOGY
Gut microbiota composition is complex and multifactorial. Individual composition is influenced by environmental and genetic factors in a polygenic model [12,13 && ]. Not surprisingly, abundance in Gram-positive organisms mapped with several inflammation-related genes such as cytokine Il22 and Irak3, a kinase regulating the MyD88-dependent Toll-like receptor (TLR) pathways [12] . The expression of Irak4, another kinase involved in TLR pathway, correlates with abundance of beneficial Roseburia ssp. in a study of the genetic determinants of the microbiome, whereas Akkermansia muciniphila is mapped with lipopolysaccharide-binding protein (Lbp) and bactericidal permeability-increasing protein (Bpi), an antibiotic secreted protein targeting Gram-negative bacteria [14 & ]. Diet is an environmental factor that critically reshapes the microbial ecology and therefore the microbial-mammalian symbiotic relationship. Diet drives the functional convergence of microbiomes across various species and habitats [15] . High-fat diet (HFD) rapidly alters the gut microbiome [16 & ] and long-term dietary patterns associated with the distribution of enterotypes: carbohydrate diets are linked with the Prevotella enterotype whereas animal protein and fats are linked with the Bacteroides enterotype [17] .
The host circadian clock influences gut microbial ecology through feeding and diurnal rhythms; long-distance travel and jet lag result in the disruption of this molecular clock and feeding rhythms thereby inducing dysbiosis, which promotes impaired glucose tolerance [18 && ]. In fact, travel influences the microbiome even in the absence of jet lag, as local diets exert a key influence on gut motility and the microbiome, even in the absence of disruptions of the circadian clock [19 && ].
KEY POINTS
The gut microbiome has a complex and modular architecture.
Numerous genetic and environmental factors affect the microbiota ecology.
Microbial-mammalian metabolic axis is a symbiotic relationship.
Dietary interventions and microbiota transplants are successful avenues for sustainable beneficial alterations of the microbiome.
Deep characterization of the microbiome by metagenomics and metabolomics can predict health and response to treatments.
Age is a major factor related to microbiome architecture, starting with the ecological dichotomy observed between C-section and natural births. The maturation of the microbiome in the first few years therefore has a critical impact on a person's health. For instance, antibiotics knock down gut bacteria and destabilize microbial ecology. There is an early life developmental window in which the microbiome can be disrupted by low-dose penicillin treatment, resulting in long-term metabolic programming [20 && ]. However, this perturbation provides an opportunity for the microbial ecology to evolve towards different equilibria, and therefore different microbiome compositions and functions. In some cases, antibiotic therapy also results in the development of abnormal microbial ecologies such as opportunistic Clostridium difficile infections. Likewise, gut microbiota composition in the elderly populations correlates with frailty, co-morbidity, nutritional status and inflammation [21] .
Surprisingly, dietary supplements such as artificial sweeteners have a direct impact on the gut microbial ecology and gene function, which then promote impaired glucose tolerance [22 && ]. Antidiabetic drug metformin also has a spectacular impact on the microbiome in animals and in humans [23 && ]. Also, diet heavily influences the production of microbial metabolites by the gut microbiota. This review will address, in particular, the impact of three microbial metabolite families involved in the microbial-mammalian metabolic axis and in human health (SCFAs, methylamines and indoles).
MICROBIAL METABOLITES FROM DIETARY FIBRE FERMENTATION IMPACT HOST METABOLISM
Consumption of dietary products rich in fibre has proven benefits for the human health, either improving insulin sensitivity or inflammatory parameters [24] . Interestingly, in both cases, gut microbial metabolism has been postulated as the link mediating these effects [24, 25] . As many plant-derived carbohydrates are partially or totally resistant to human digestion in small intestine, they progress into the colon where they can undergo bacterial transformation. As a result, carbohydrate fermentation and bacterial cross-feeding produce a range of Considering the above-mentioned effects, it is relevant to understand the relative contribution of diet and microbiota composition to SCFA production. Dietary carbohydrate intake has been shown to impact the faecal levels of SCFA, but the effect on butyrate was not proportional to the variation of total SCFA, suggesting that specific microbial groups (e.g. butyrate-producing Roseburia-Eubacterium rectale groups) may have a higher dependence on diet [24,31].
MICROBIAL CONVERSION OF DIETARY CHOLINE INTO METHYLAMINES IMPACTS INSULIN RESISTANCE AND ATHEROSCLEROSIS
Methylamines are metabolites produced by gut microbiota from the degradation of choline in tri-
The estimated daily choline intake in adults is of 222-415 mg, mainly obtained from meat products but also from dairy products, egg, grains, grain-based products and sea-
The bacterial species degrading choline into TMA were predicted in silico [33] . An in-vitro screening of 79 human intestinal isolates validated that CutC and CutD expressing species were TMA producers, as well as Edwardsiella tarda despite the absence of Cut cluster, this latter finding having been met with scepticism [34 && ]. TMA diffuses through the host's bloodstream to the portal vein and is detoxified into TMA-N-oxide (TMAO) by the hepatic flavin-monooxygenase 3 (FMO3).
Raised TMAO plasma concentration was associated with cardiovascular risk in several studies [35] . Furthermore, TMAO dietary supplementation enhanced heart failure in an in-vivo model [36] . A recent study proposed the use of 3,3-dimethyl-1- ]. Altogether, these studies suggest to consider the role of the TMA ! (FMO3) ! TMAO reaction as a whole process rather than TMAO's role alone.
TRYPTOPHAN IS METABOLIZED INTO A RANGE OF INDOLE-CONTAINING DERIVATIVES
Tryptophan is an essential amino acid particularly abundant in egg white, red meat, poultry, fish, cheese, peanuts and also in some seeds [43] . According to the World Health Organization, the daily recommended dose of tryptophan for an adult human is 4 mg/kg of body weight [43] . Apart from its role in protein biosynthesis, tryptophan is also a biochemical precursor of serotonin and niacin. Recent studies have pointed out a novel potential role for tryptophan in metabolic outcomes: in humans, tryptophan levels are associated with an increased risk of type 2 diabetes [44, 45] whereas in rats, interestingly, its supplementation decreases fat deposition and enhances both protein synthesis and fatty acid oxidation [46 & ]. A recent study in a fish model also points out a possible role on the improvement of the intestinal barrier integrity and immune function [47] .
Tryptophan can also enter a complex network of bacterial-based metabolic reactions, producing a range of gut bacterial metabolites that lately impact different aspects of the host's health. 
THERAPEUTIC INTERVENTIONS RESHAPING THE GUT MICROBIOME ECOLOGY
Evidence from high-throughput technologies (e.g. metagenomics and metabolomics) supports the idea that the gut microbiota composition is a paramount aspect of the mammalian-microbial symbiotic relationship and, therefore, greatly affects human health and disease. Gene richness, a marker of metabolic health, is actionable by dietary interventions: gene count increases as obese patients follow a weight loss diet [52] . Moreover, Shoaie et al. [53 && ] implemented a mathematical approach modelling the metabolism of key members of the microbiome of these patients and predicted the impact of the microbiome on faecal and circulating SCFAs and amino acids during this weight loss programme.
Postprandial glycemic responses are highly variable between two patients and this variability is associated with a range of dietary, clinical and metagenomic factors [54 && ]. Zeevi et al. developed a predictive model for postprandial glycemic responses based on anthropometric measurements, dietary questionnaires and faecal metagenomes and used it to design personalized diets. These tailored dietary interventions were able to modify the gut microbiota and to increase populations of bacteria previously reported as beneficial.
Reshaping the gut microbial ecosystem with the utilization of functional food ingredients is a
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popular therapeutic strategy to improve host health. In particular, prebiotics are defined as fermented ingredients that beneficially affect the host by selectively stimulating the growth and/or the activity of colonic microbiota [55] . Prebiotics consist of oligosaccharides or short-chain polysaccharides whose effect is mediated by the enhancement of beneficial microbes Bifidobacteria and Lactobacilli and the pro- ]. In humans, however, prebiotic studies vary in quality and outcomes depending on age, dietary habits and prebiotic doses [60] . Several clinical randomized studies showed an improved inflammatory status, glucose sensitivity and an influence on satiety on overweight patients [56 && ]. Another approach to remodel the gut microbial ecology is the use of probiotics, usually a single microbial species that enhances intestinal balance by changing the composition and activity of gastrointestinal microbiota [55] . Probiotics turned out to be efficient in improving lactose digestion, reducing diarrhoea and bloating, restoring a symbiotic ecosystem after an antibiotic intervention, and enhancing glucose sensitivity in humans [55] but no clear effects of probiotics on obesity and metabolic outcomes were demonstrated in human studies [61] .
However, oral probiotic doses are in general more than one thousand times lower than the trillions of endogenous gut microbes and prebiotic administration temporarily influence the microbiome therefore not having a lasting effect on microbial ecology [62 & ]. Although dietary and probiotic interventions impact the microbiome, faecal microbiota transplantation (FMT) allows the efficient transfer of an established microbial community together with its ecological properties. This approach has been highly successful and demonstrated that microbial communities could transfer disease phenotypes such as obesity [63] or nonalcoholic fatty liver disease [64] . The FMT approach has been trialled for metabolic syndrome in human clinical studies [65] but has never been confirmed since that time.
FMTs have also reported efficiency in the reduction of the recurrence of C. difficile infection and held promising effects on ulcerative colitis and Crohn's diseases [66 & ]. A better understanding of the interplay between the prebiotics, probiotics, bacterial transplants and the gut microbiota is the prerequisite for optimising their uses in the treatment of inflammatory disorders and metabolic diseases.
CONCLUSION
The understanding of the importance of the microbiota in health and disease is now established. The interactions between gut microbiota and host can be described as a symbiotic balance. Research is now mainly focusing on the gut microbiota dynamics and how this influences interactions with the host. Recent discoveries have shown that some metabolites produced by gut act as signalling molecules on the host and by this mechanism could directly modulate host metabolism. These discoveries help the development of specific strategies to modify gut microbiota that will allow us to develop more effective treatments of metabolic diseases.
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